Alterity Therapeutics Ltd. announced the successful completion of its Phase 2 program for its lead asset, ATH434, in multiple system atrophy $(MSA)$. The company reported that results from the Phase 2 trials demonstrated ATH434 to be safe and well-tolerated, with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments. Alterity stated it is now advancing ATH434 towards a pivotal Phase 3 clinical program in MSA, targeting entry into an estimated $2.4 billion market opportunity. The company outlined three key objectives for 2026: finalizing the regulatory strategy to initiate the Phase 3 trial, deepening external engagement, and expanding intellectual property protection. An End-of-Phase 2 meeting with the FDA is planned for mid-2026, which will be the final regulatory step before the Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629287-en) on January 21, 2026, and is solely responsible for the information contained therein.